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The expression levels of CT10 regulator of kinase (Crk) and
Crk-like (CrkL) are elevated in many human cancers, including
glioblastoma (GBM), and are believed to contribute to poor
prognosis. Although Crk and CrkL have been proposed as
therapeutic targets in these tumors, the lack of a reliable,
quantitative assay to measure Crk and CrkL activity has hindered development of inhibitors. Here, we knocked down Crk,
CrkL, or both using siRNAs in a human GBM cell line, U118MG, to determine the respective, quantitative contributions
of Crk and CrkL to cellular phenotypes. The combined use of
speciﬁc and potent Crk and CrkL siRNAs induced effective
knockdown of CrkII, CrkI, and CrkL. Whereas Crk knockdown
did not affect cell morphology, proliferation, adhesion, or invasion, CrkL knockdown caused shrinkage of cells and inhibition of cell proliferation, adhesion, and invasion. Crk/CrkL
double knockdown resulted in more pronounced morphological alterations and more robust inhibition of proliferation,
adhesion, and invasion. Furthermore, Crk/CrkL double
knockdown completely blocked cell migration, and this effect
was rescued by transient overexpression of CrkL but not of Crk.
Quantiﬁcation of protein levels indicated that CrkL is
expressed more abundantly than CrkII and CrkI in U-118MG
cells. These results demonstrate both the predominant role of
CrkL and the essential overlapping functions of Crk and CrkL
in U-118MG cells. Furthermore, our study indicates that
migration of U-118MG cells depends entirely on Crk and CrkL.
Thus, impedance-based, real-time measurement of tumor cell
migration represents a robust assay for monitoring Crk and
CrkL activities.

Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor, with an average of 15 months of
survival after diagnosis (https://www.cancer.gov/about-nci/
organization/ccg/research/structural-genomics/tcga/studiedcancers/glioblastoma) (1). Approximately 13,310 new cases of
GBM were estimated in the United States in 2019, according
to the American Brain Tumor Association (https://www.
abta.org/wp-content/uploads/2018/12/glioblastoma-anaplastic-

astrocytoma.pdf). Standard therapy for GBM is surgical
removal of the tumor, followed by ionizing radiation and
chemotherapy. The success of this approach depends primarily
on how completely the tumor is surgically resected, in part
because effective chemotherapy is not available. However,
complete resection of GBM is challenging because the tumor
is heterogeneous and highly inﬁltrative (2–4). Recent reports
suggest that GBM cells are very motile, and degree of motility
negatively correlates with survival of patients (5, 6). Therefore,
it is necessary to develop effective chemotherapy to minimize
inﬁltration of tumor cells into surrounding tissues (7). A
combination of surgery, radiation, and chemotherapy that
blocks GBM cell motility is required to improve prognosis.
CT10 regulator of kinase (Crk) and Crk-like (CrkL) are
overexpressed in multiple human cancer types, including GBM
(8–10), breast cancer (11–13), non-small cell lung cancer
(14–16), gastric cancer (17–19), cervical cancer (20, 21),
ovarian cancer (22, 23), endometrial carcinoma (24), oral
squamous cell carcinoma (25), bladder cancer (26), rhabdomyosarcoma (27), thyroid cancer (28), pancreatic cancer (29),
and colorectal cancer (30). Reduced expression of either Crk or
CrkL, by RNA interference-mediated gene knockdown,
inhibited cell adhesion, migration, invasion, proliferation, and
in vivo tumor growth of many cancer cell lines such as GBM
(31, 32), breast cancer (11–13), gastric cancer (17, 33), cervical
cancer (34), ovarian cancer (22, 23, 35), prostate cancer
(36, 37), bladder cancer (26), oral squamous cell carcinoma
(25), synovial sarcoma (38), rhabdomyosarcoma (27), hepatocellular carcinoma (39), and head and neck squamous cell
carcinoma (40) cells. In addition, ablation of Crk by CRISPR/
Cas9 inhibited in vivo growth of breast cancer cells (41), and
ablation of both Crk and CrkL by CRISPR/Cas9 inhibited
colorectal cancer cell adhesion, migration, invasion, and proliferation (42). Furthermore, elevated expression of Crk or
CrkL correlated with the poor prognosis in GBM (9), lung
cancer (16, 43), gastric cancer (19), ovarian cancer (44), oral
squamous cell carcinoma (25), pancreatic cancer (29), and
colorectal cancer (30). Therefore, Crk and CrkL have been
proposed as potential therapeutic targets in these cancers.
Although it is well known that Crk and CrkL are structurally
and functionally similar, the majority of studies address the
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Cell migration is the outcome of Crk and CrkL
role of either Crk or CrkL individually in knockdown or
overexpression experiments in cancer cell models, in gene
expression analyses of cancer tissues, and in outcome analyses
of patient survival. Thus, the scientiﬁc literature has created an
enigma; it appears that Crk and CrkL are important in several
cancers, but it is unclear whether a single one of these genes is
the culprit or both in combination. This uncertainty is compounded by the fact that most knockdown studies, targeting
either Crk or CrkL alone, did not investigate the possibility of
cross-regulation. Therefore, the siRNAs or shRNAs used in
these studies may not have speciﬁcally inhibited either Crk or
CrkL, because of their high level of sequence similarity, as they
may have also affected expression of the paralog. Similarly, a
study in which shRNAs were used to reduce expression of
CrkII, CrkI, and CrkL simultaneously did not ascertain
whether the phenotypes observed required knockdown of Crk
and CrkL in combination or just one of the genes alone (12).
Recently, Franke et al. (42), using individual and double
knockout cells, demonstrated that Crk and CrkL both
contribute to migration and invasion of colon cancer cells.
Previously, we reported that Crk and CrkL play essential
overlapping roles in many biological processes, including
neuronal migration, neuromuscular synapse formation,
podocyte morphogenesis, T cell migration into sites of
inﬂammation, lens ﬁber cell elongation, and natural killer cell
expansion and differentiation during mouse cytomegalovirus
infection (45–50). In addition, we induced knockout of Crk
and CrkL in cultured ﬁbroblasts using the Cre-loxP recombination and demonstrated that Crk and CrkL play essential
overlapping roles in cell structure, motility, and growth (51,
52). These studies indicate that a more systematic and
comprehensive analysis is required to untwine the individual
or collective contributions of Crk and CrkL to tumor cell
biology. This concern prompted us to compare single and
double knockdown of Crk and CrkL in a GBM cell line using a
systematic and quantitative approach to address effects on cell
adhesion, migration, invasion, and proliferation. Our results
demonstrate that CrkL, which is more abundantly expressed
than CrkII and CrkI, plays a more prominent role than Crk
and that Crk and CrkL play essential overlapping roles in cell
adhesion, migration, invasion, and proliferation in the GBM
cell line investigated. Our study supports the use of
impedance-based real-time measurement of cell migration as a
quantitative assay for monitoring activities of Crk and CrkL.

Results
Optimization of GBM cell transfection
Previously, we achieved a rapid and efﬁcient transfection of
mouse embryonic ﬁbroblasts with synthetic mRNA (synRNA)
using the Neon electroporation system (52). We applied this
method to transfect the GBM cell line U-118MG. When U118MG cells were electroporated with synthetic green ﬂuorescent protein mRNA (synGFP), many cells showed strong
green ﬂuorescence (Fig. S1A). The viability of cells was indirectly assessed by the initial measurement of the WST-1 signal.
Upon electroporation, viabilities were not different among
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cells electroporated without and with synGFP (Fig. S1B; 208 ±
14 for none and 199 ± 8 for synGFP). The growth rates over
2 days were also not affected signiﬁcantly by the electroporation of cells with synGFP (Fig. S1C). The results suggest that
RNA can be efﬁciently introduced to U-118MG cells by
electroporation using the Neon system without any noticeable
nonspeciﬁc changes in cell viability and proliferation.
Testing of Crk siRNAs
To ﬁnd siRNAs that induce efﬁcient and speciﬁc knockdown of Crk, we transfected U-118MG cells with four different
siRNAs targeting the SH2 or SH3 domains of the human CRK
gene (Fig. 1A). Then, we examined the level of Crk and CrkL
proteins produced at 3 days posttransfection (DPT). Crk siRNAs 7, 9, and 10 reduced expression levels of CrkII and CrkI
by more than 70% without affecting CrkL expression (Fig. 1, B
and C). Crk siRNA 10 was the most effective at reducing CrkII
and CrkI levels (83.2 ± 2.9% and 92.6 ± 0.2%, respectively). On
the other hand, Crk siRNA 8 reduced the CrkI and CrkII
expression by 42.0 ± 4.4% and 44.8 ± 8.8%, respectively.
Although Crk siRNAs 7 and 9 reduced CrkI and CrkII
expression by similar amounts, only Crk siRNA 7 decreased
the phospho-p130Cas level signiﬁcantly, suggesting that the
inhibition of p130Cas phosphorylation by Crk siRNA 7 might
not be caused by the reduction of CrkII and CrkI. We also
examined the effect of gene knockdown on cell morphology.
Whereas Crk siRNAs 7 and 8 caused visible morphological
alterations, Crk siRNAs 9 and 10 did not cause apparent
morphological alterations (Fig. 1D), suggesting that the
morphological alterations caused by Crk siRNAs 7 and 8 may
not be mediated by the reduction in the CrkI and CrkII levels.
Interestingly, CrkI expression was decreased by Crk siRNA 9,
although CrkI lacks the target site for the siRNA. It is unclear
whether there is any feedback regulation of CrkI and CrkII at
the mRNA and protein levels. We selected Crk siRNA 10 for
future studies because it was the most potent siRNA among
those tested without affecting the phospho-p130Cas level and
the cell morphology.
Testing of CrkL siRNAs
We took a similar approach to ﬁnd siRNAs that induce
speciﬁc knockdown of CrkL. U-118MG cells were transfected
with four different siRNAs targeting the N-terminal SH3
domain of the human CRKL gene (Fig. S2A), and protein levels
were examined at 3 DPT. CrkL siRNA 7 was the most effective,
reducing CrkL expression by 71.3 ± 0.9%. However, it also
reduced the levels of CrkI and phospho-p130Cas signiﬁcantly
(Fig. S2, B and C). In addition, CrkL siRNA 7 appeared to
induce modest morphological alterations (Fig. S2D). Therefore, we tested additional siRNAs to ﬁnd more potent and
speciﬁc CrkL siRNAs (Fig. 2A). We used nontargeting siRNA 1
(NT1) as a negative control. Whereas CrkL siRNA 23 showed
similar effects to CrkL siRNA 7, both CrkL siRNAs, 22 and 24,
showed more robust reductions in CrkL expression (by 79 ±
2.4% and 77.5 ± 3.3%, respectively) without affecting CrkII,
CrkI, and other proteins tested (Fig. 2, B and C). While CrkL
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Figure 1. Electroporation of U-118MG cells with Crk siRNAs. A, a schematic diagram of the target areas of Crk siRNAs. B, U-118MG cells were electroporated with Crk siRNAs (40 pmol in 10 μl cell suspension), and total cell lysates were prepared at 3 days posttransfection (DPT) for the Western blot
analyses. Protein levels upon siRNA transfection were compared with those upon electroporation without siRNAs. Alpha-tubulin and vinculin levels were
measured as controls. C, protein bands were quantiﬁed using the Odyssey system, and their mean ± standard deviation (SD) values are shown. *p < 0.05,
**p < 0.01, compared with the control (none). D, phase-contrast images of live cells were taken at 3 DPT using the EVOS system. Representative images are
shown. Scale bar: 400 μm. Crk, CT10 regulator of kinase.

siRNA 22 did not cause morphological alterations, CrkL
siRNA 24 slightly affected cell morphology (Fig. 2D). The results suggest that CrkL siRNA 22 may be the most speciﬁc and
potent siRNA among those tested. Notably, the target
sequence for both CrkL siRNAs 7 and 23 was identical,
although they were purchased from different companies,
which explains their similar effects. These results demonstrate
the reproducibility of our experiments.
Next, we tested different concentrations of Crk and CrkL
siRNAs to identify the optimal amounts of siRNAs to produce
potent and speciﬁc gene knockdown. The knockdown effect of
Crk siRNA 10 on the CrkII and CrkI levels increased as the
siRNA concentration increased and reached the maximum at
around 40 pmol (85.4 ± 4.1% for CrkII and 92.5 ± 2.6% for CrkI)
(Fig. S3, A and B). The knockdown effect caused by Crk siRNA
10 appears to be very speciﬁc because, at levels up to 80 pmol, it
did not affect the expression of CrkL or other proteins tested.
Crk siRNA 10 did not induce any apparent morphological alterations (Fig. S3C). In contrast, the knockdown of CrkL by
siRNA 22 seemed to continually increase in a dose-dependent
manner across the range tested. Therefore, we examined
whether the combined transfection of cells with CrkL siRNAs
22 and 24 induces more potent knockdown effects. When cells

were transfected with CrkL siRNAs individually, both CrkL
siRNAs 22 and 24 exhibited similar reductions in CrkL
expression at 40 and 80 pmol (Fig. S4, A and B). When cells
were transfected with both CrkL siRNAs 22 and 24 in combination, the inhibitory effect at a total of 80 pmol (82.8 ± 1.4%)
was slightly higher than at a total of 40 pmol (79.1 ± 1.5%). The
inhibitory effect induced by the combined transfection was a
little higher than that produced by transfections with the individual siRNAs (76.5 ± 2.2% and 79.2 ± 1.9% for CrkL siRNAs 22
and 24, respectively) even though the total amount of siRNAs
was 80 pmol in both cases. The morphological alterations
associated with the combined transfection with CrkL siRNAs 22
and 24 appeared to be similar to CrkL siRNA 22 alone at a total
of 80 pmol (Fig. S4C). Therefore, we chose to use both CrkL
siRNAs 22 and 24 (40 pmol each) to induce CrkL knockdown.
Effects of Crk and CrkL knockdown on cell proliferation and
morphology
We transfected U-118MG cells with Crk siRNA 10 and
CrkL siRNAs 22 and 24 and carried out time course experiments to examine when single and double knockdown of Crk
and CrkL reached peak effects. As shown in Figure 3, A and B,
the CrkII and CrkI levels, upon Crk knockdown, continued to
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Figure 2. Electroporation of U-118MG cells with additional CrkL siRNAs. A, a schematic diagram of the target areas of CrkL siRNAs. B, U-118MG cells
were electroporated with CrkL siRNAs (40 pmol in 10 μl cell suspension), and total cell lysates were prepared at 4 DPT for Western blot analyses. Protein
levels upon siRNA transfection were compared with those upon electroporation without siRNAs (none) or with nontargeting siRNA 1 (NT1). Alpha-tubulin
and vinculin levels were measured as controls. C, protein bands were quantiﬁed using the Odyssey system, and their mean ± SD values are shown. **p <
0.01, compared with the control (NT1). D, phase-contrast images of live cells were taken using the EVOS system at 4 DPT. Representative images are shown.
Scale bar: 400 μm. Crk, CT10 regulator of kinase; CrkL, Crk-like; DPT, days posttransfection.

decrease until 4 DPT, at which point the inhibitory effects
reached a maximum (91.4 ± 1.4% for CrkII and 96.3 ± 0.4% for
CrkI). Upon CrkL knockdown, the CrkL protein level
decreased until 3 DPT, reaching maximal inhibition at 3 and 4
DPT (by 75.8 ± 12.0% and 75.7 ± 4.9%, respectively). Upon the
double knockdown of both Crk and CrkL, protein levels of
CrkII, CrkI, and CrkL were the lowest at 4 DPT. The phosphop130Cas level in cells undergoing double knockdown was
signiﬁcantly lower than the control levels at 3 and 4 DPT.
Because ﬁbroblast proliferation was blocked by ablation of Crk
and CrkL using the Cre-loxP recombination (52), we examined
cell proliferation under single and double knockdown conditions. Decreases in cell proliferation by CrkL knockdown and
Crk/CrkL double knockdown became evident at 4 DPT
(Fig. 4A), which is consistent with the prior observation that
the maximum knockdown occurred at 4 DPT. When assessed
by the growth rate, Crk knockdown did not affect proliferation
of U-118MG cells, whereas CrkL knockdown inhibited cell
proliferation by approximately 25%, compared with NT1
(Fig. 4B). Double knockdown of Crk and CrkL also exhibited a
similar extent of inhibition to CrkL knockdown, suggesting
that cell proliferation partially depends on CrkL.
Next, we analyzed cell morphology to determine whether
knockdown of Crk and CrkL affected cell structure. A
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comparison of phase-contrast images of cells taken using
EVOS suggested that cells looked different with CrkL knockdown and Crk/CrkL double knockdown at 3 to 5 DPT
(Fig. S5). To analyze the cell morphology quantitatively, we
stained the cells with ﬂuorophore-conjugated phalloidin and
calculated the cytoplasmic area and roundness. Images of
phalloidin-stained cells suggested that cells looked sparse with
Crk/CrkL double knockdown at 3 to 5 DPT, compared with
the controls (none and NT1) (Fig. 4C). The measurement of
cytoplasmic area indicated that cells gradually spread with an
increase in cytoplasmic area as the day progressed after the
transfection and plating. The cytoplasmic areas of the control
cells (none and NT1) increased gradually from 1 DPT to 5
DPT (Fig. 4D). The gradual spreading of cells on culture dishes
was moderately inhibited upon Crk/CrkL double knockdown
at 3 to 5 DPT (1035 ± 123 μm2, compared with 1281 ±
139 μm2 for NT1 at 5 DPT) (Fig. 4D). The inhibition of cell
spreading or the decrease in cell surface area in the absence of
Crk and CrkL is consistent with our previous reports with ﬁbroblasts (51, 52). On the other hand, Crk knockdown cells
exhibited enhanced spreading at 4 and 5 DPT, but the increases were not signiﬁcant when the experiment was repeated
(data not shown). Lack of correlation between cell number and
cell surface area in a ﬁeld of view for each sample at 5 DPT
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Figure 3. Time courses of Crk and CrkL knockdown. A, U-118MG cells were electroporated with NT1 (80 pmol), Crk siRNA 10 (40 pmol), CrkL siRNAs 22 (20
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CrkL, Crk-like; DPT, days posttransfection; NT1, nontargeting siRNA 1.

suggests that the altered cell morphology may not be the
outcome of cell density changes (data not shown).
We also investigated the roundness of cells. Control cells
became less rounded as the days progressed after transfection
and plating (Fig. 4E). These decreases in roundness were
consistent with increases in the cytoplasmic area as cells
continued to spread (Fig. 4D). The decrease in roundness
signiﬁcantly subsided upon CrkL knockdown and Crk/CrkL
double knockdown (Fig. 4E). In contrast, Crk knockdown did
not affect the change in roundness. The morphological

alterations, assessed by the cytoplasmic area and the roundness, were more signiﬁcant with Crk/CrkL double knockdown
than with CrkL knockdown (Fig. 4, D and E). In contrast, the
nuclear area and roundness of control cells did not change
after transfection and plating and were not affected by
knockdown of Crk and CrkL (Fig. S6, A and B). The results
suggest that reorganization of the cell cytoskeleton is defective
in the absence of Crk and CrkL, with CrkL playing a predominant role. The results also emphasize that quantitative
analyses are critical in comparing single and double
J. Biol. Chem. (2021) 296 100390

5

Cell migration is the outcome of Crk and CrkL

A

D

B

**
**

Area (um2)

1500
900
0.6
0.5

**
**

0.4

0.2

dKD

5

CrkL KD

4

NT1

3
DPT

Crk KD

2

None

0.0

1

1

1000

**
500

**

**

0.3

0.1

90

E

Roundness

Growth rate

A450-A690, normalized

None
NT1
Crk KD
CrkL KD
dKD

0
0
0.5

1

2

**
**

3

4

**
**

**

5
None
NT1
Crk KD
CrkL KD
dKD

**
0
0

C
NT1

Crk KD

2
3
DPT

CrkL KD

4

5

dKD

5 DPT

4 DPT

3 DPT

2 DPT

1 DPT

None

1

Figure 4. Effects of Crk and CrkL knockdown on cell proliferation and morphology. A, U-118MG cells were electroporated with NT1 (80 pmol), Crk
siRNA 10 (40 pmol), CrkL siRNAs 22 (20 pmol) plus 24 (20 pmol), or with Crk and CrkL siRNAs together, and cell proliferation was quantitatively measured
using WST-1. The A450–A690 values are presented in the logarithmic scales. B, exponential trendlines for the WST-1 assay graphs were drawn, and their
slopes, the coefﬁcients of x, are presented as the rates for exponential cell growth. **p < 0.01, compared with NT1. C–E, after cells were transfected with Crk
and CrkL siRNAs, the cells were ﬁxed at the indicated DPT and stained with phalloidin and DAPI to visualize the cytoplasm and the nucleus, respectively.
Representative images are shown (C). Scale bar: 400 μm. Cell surface areas (D) and roundness (E) of phalloidin-stained objects were calculated according to
the Experimental procedures, and their mean ± SD values are shown. **p < 0.01, compared with both none and NT1 at the same DPT. Two independent
experiments were carried out, and the results were reproducible. Crk, CT10 regulator of kinase; CrkL, Crk-like; DPT, days posttransfection; NT1, nontargeting
siRNA 1.

knockdown effects of Crk and CrkL to obtain a clear view of
their essential overlapping functions.
We examined distribution of Crk and CrkL expression in the
cell population upon single and double knockdown using ﬂow
cytometry analyses. Cells with single and double knockdown
were ﬁxed and stained with anti-Crk and anti-CrkL antibodies
that were used for the Western blot analyses. To make any
changes caused by the knockdown easily interpretable, we
divided the ﬂuorescence signal into 11 bins and conducted a bin
analysis. As shown in Figure S7, A and B, the signal detected by
the anti-Crk antibody shifted to the left upon Crk knockdown
and Crk/CrkL double knockdown, suggesting that the signal is
speciﬁc to Crk. There was a range of Crk expression in control
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cells, which moved to the left upon Crk knockdown. However, a
majority of Crk knockdown cells exhibited still higher signals
than the control cells, suggesting that most cells had a substantial, but not complete, knockdown. On the other hand, the
signal detected by the anti-CrkL antibody did not shift upon
CrkL knockdown and Crk/CrkL double knockdown, suggesting
that the signal is not speciﬁc to CrkL (Fig. S7, A and C).
Effects of Crk/CrkL knockdown after harvesting cells and replating at 3 DPT
Crk and CrkL have been reported to contribute to adhesion,
migration, and invasion of GBM cell lines (8–10, 31, 32). To

Cell migration is the outcome of Crk and CrkL
quantitatively analyze the effects of single and double knockdowns of Crk and CrkL on cell adhesion, migration, and invasion, we recently established impedance-based real-time cell
assays using the xCELLigence system (Agilent) (53). The system provided real-time, quantitative, and comprehensive analyses of cancer cell behavior (9, 10, 53). However, unlike the
other assays that we used, real-time cell analysis requires
suspended cells. Because gene knockdown of Crk and CrkL
takes 3 to 4 days to reach maximum after transfection, we
harvested cells at 3 DPT and carried out impedance-based cell
analyses as well as other experiments. Because we carried out
the previous experiments without harvesting cells after

transfection, we repeated the previous experiments under
modiﬁed culture conditions. First, we examined the protein
levels at 4 DPT (1 day after harvesting and re-plating cells) to
compare the results between the two experimental conditions.
As shown in Figure 5, A and B, Crk knockdown decreased the
CrkII and CrkI expression to 7.6 ± 1.1% and 3.0 ± 5.6% at 4
DPT (compared with 8.6 ± 1.4% and 3.7 ± 0.4%, respectively in
Fig. 3B). CrkL knockdown decreased CrkL expression to 11.3 ±
2.5% (compared with 24.3 ± 4.9% in Fig. 3B). In addition,
alpha-tubulin levels observed in the Crk/CrkL double knockdown conditions were similar in previous (Fig. 3B) and current
(Fig. 5B) experiments. These ﬁndings suggest that reductions

NT1
Crk KD
CrkL KD
dKD

CrkL

38

NT1
Crk KD
CrkL KD
dKD

30

D
NT1
Crk KD
CrkL KD
dKD

aTubulin

Vinculin

** **

C

80

0.6
0.5

*

0.4

**

0.3
0.2
0.1
0.0

4

E
NT1

** **

Crk KD

5
DPT

6

CrkL KD

dKD

15
50

0

**
**

CrkL KD

CrkI

**

20

Crk KD

CrkII

30
25

A450-A690, normalized

38

*

40

pY-p130Cas

p130Cas

**

NT1

160
125
90
50

60

p130Cas

pY-p130Cas

**

**

Growth rate

38
160
125
90

80

CrkL

aTubulin

50

100

CrkI

Vinculin

125
90
70

120

CrkII

260

Protein expression (% of control)

B

A

dKD

Figure 5. Effects of Crk and CrkL knockdown after re-plating at 3 DPT. A, U-118MG cells were electroporated with NT1 (80 pmol), Crk siRNA 10 (40
pmol), CrkL siRNAs 22 (20 pmol) plus 24 (20 pmol), or with Crk and CrkL siRNAs together. The cells were harvested and re-plated at 3 DPT, and total cell
lysates were prepared at 4 DPT for Western blot analyses. Protein levels upon siRNA transfection were compared with NT1. Alpha-tubulin and vinculin levels
were measured as controls. B, protein bands were quantiﬁed using the Odyssey system, calculated as percentages of the control (NT1), and their mean ± SD
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Effects of Crk/CrkL knockdown on cell adhesion, migration,
and invasion
We induced knockdowns and harvested cells at 3 DPT for
impedance-based real-time cell analyses using xCELLigence.
First, we tested the effects of Crk and CrkL knockdown on
adhesion of GBM cells to ﬁbronectin-coated plates. Adhesion
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of control cells to ﬁbronectin following NT1 transfection took
place quickly and reached a maximum (1.19 ± 0.07) after 1 h
(Fig. 6A). In the case of Crk knockdown, there was a modest
increase in maximum adhesion (1.42 ± 0.15). On the other
hand, CrkL knockdown alone resulted in decreased adhesion
(0.58 ± 0.06). Crk/CrkL double knockdown further reduced
cell adhesion (0.25 ± 0.04). Our results suggest that Crk does
not seem to play a signiﬁcant role in cell adhesion in the
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in CrkII, CrkI, and CrkL protein levels are comparable between the two experiments.
Phospho-p130Cas levels were signiﬁcantly lower in cells
undergoing Crk knockdown and Crk/CrkL double knockdown
at 4 DPT (Fig. 5B). In the previous experiment, phosphop130Cas was signiﬁcantly lower at 4 DPT only with Crk/
CrkL double knockdown (Fig. 3B). Although it is unclear how
the change in cell culture inﬂuenced this difference, cell
adhesion and spreading after re-plating under the Crk and
CrkL knockdown condition may have rendered the phosphop130Cas level more vulnerable. p130Cas is known to be
phosphorylated upon ﬁbroblast adhesion (54), and cell
spreading was delayed in the absence of p130Cas (55). In
contrast, cells adhered and spread before complete suppression of CRK/CRKL gene expression in the previous experiment. Nevertheless, Crk/CrkL double knockdown resulted in a
decrease in p130Cas phosphorylation under both conditions.
Next, we compared the effects of Crk and CrkL knockdown
on cell proliferation in the two culture conditions. Similar to
the previous experiment (Fig. 4, A and B), Crk knockdown did
not affect cell proliferation (Fig. 5, C and D). In addition, inhibition of cell proliferation following CrkL knockdown was
consistent. On the other hand, Crk/CrkL double knockdown
induced more potent inhibition in cell proliferation (42%,
compared with 19% in Fig. 4B). This difference suggests that
we observed a more potent inhibitory effect caused by double
knockdown because we started the cell proliferation assay after
3 DPT, a time when Crk and CrkL were fully suppressed. The
current experiment shows modest inhibition of cell proliferation by CrkL knockdown and a potent inhibition by Crk/CrkL
double knockdown. We also compared the effects of Crk and
CrkL knockdown on cell morphology. Phase-contrast imaging
at 4 DPT (1 day after re-plating) revealed morphological alterations induced by CrkL knockdown and by Crk/CrkL
double knockdown (Fig. 5E). The morphological alterations
were more pronounced than those observed in the previous
experiment in the absence of re-plating (Fig. S5), suggesting
that cell adhesion and spreading after re-plating may have
enhanced the knockdown effects. Both the previous and the
current experiments consistently show modest morphological
alterations resulting from CrkL knockdown and more signiﬁcant morphological alterations associated with Crk/CrkL
double knockdown. Comparison of the results obtained from
the two culture conditions indicate that harvesting and replating cells at 3 DPT is a reasonable and effective approach
to investigate the effects of knockdown. This approach allowed
us to observe knockdown effects more clearly by avoiding the 1
to 3 DPT period when the level of gene knockdown was
increasing.
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Figure 6. Effects of Crk and CrkL knockdown on cell adhesion, migration, and invasion. U-118MG cells were electroporated with NT1 (80 pmol),
Crk siRNA 10 (40 pmol), CrkL siRNAs 22 (20 pmol) plus 24 (20 pmol), or with
Crk and CrkL siRNAs together. At 3 DPT, the cells were harvested and plated
onto an E-Plate 16, and two CIM-Plates without and with Matrigel coating
for cell adhesion (A), migration (B), and invasion (C) using the xCELLigence
system according to the Experimental procedures. Cell index values were
obtained from four wells for each sample, and their mean ± SD values are
shown. Three independent experiments were carried out, and the results
were reproducible. CIM, cell invasion and migration; Crk, CT10 regulator of
kinase; CrkL, Crk-like; DPT, days posttransfection; NT1, nontargeting siRNA 1.
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presence of CrkL. However, when CrkL levels are low, cells
depend on Crk for GBM cell adhesion.
We also examined the effects of Crk and CrkL knockdown
on GBM cell migration. The cell index increased as time
passed, indicating that cells placed in the upper chamber
with low serum migrated toward the lower chamber with
high serum through the microporous membrane and
deposited onto the impedance electrode on the underside of
the upper chamber (53). The cell index for the control cells
with NT1 transfection continually increased until it reached
the maximum at approximately 11 h (Fig. 6B). Then, the cell
index slowly decreased for several hours, suggesting that
more cells, after the migration, detached from the electrode
surface into the medium in the lower chamber than the cells
that newly migrated through the membrane. Therefore, we
focused on the maximal cell index and the time for cells to
reach that maximal point for each condition. Cells with Crk
knockdown migrated at slower rates than the control cells,
reaching the maximum at about 20 h. However, maximal
migrations were similar between control and Crk knockdown cells (1.23 ± 0.06 and 1.31 ± 0.11, respectively). On the
other hand, cells with CrkL knockdown showed slower rates
of migration, and maximal migration was signiﬁcantly lower
(0.75 ± 0.01 at 26 h). These results suggest that both Crk and
CrkL contribute to cell migration, probably through different
mechanisms. Furthermore, cells with Crk/CrkL double
knockdown failed to migrate. The failure of migration by
Crk/CrkL knockdown cells was much more severe than a
projected delay in migration of CrkL knockdown cells, which
implies that Crk and CrkL cooperate and play essential
overlapping roles in GBM cell migration. The results are
consistent with our previous observations (53), and they
emphasize the importance of comparing single and double
knockdown cell populations to uncover the overlapping
functions of Crk and CrkL.
We also tested the effects of Crk and CrkL knockdown on
the GBM cell invasion. Cell invasion was measured by coating
the top of the microporous membrane with Matrigel. Unlike
cell migration, there was an initial lag phase of about 10 h
before the control cells started to invade the Matrigel and
reach the impedance electrode on the underside of the upper
chamber (Fig. 6C). After cells migrated through the Matrigel
for about 24 h, cell invasion was reduced. Cells with Crk
knockdown showed a similar pattern of invasion, reaching
maximum (1.21 ± 0.02) at 43 h. Cells with CrkL knockdown
had a more prolonged lag phase of approximately 22 h before
they migrated through the Matrigel, continuing for about 34 h
with invasion reaching maximum values at 57 h. Crk/CrkL
double knockdown further prolonged the lag phase to about
33 h, and invasion at 60 h reached lower values (0.16 ± 0.08)
than that observed following Crk knockdown (1.11 ± 0.02) or
CrkL knockdown (0.72 ± 0.03). It is unclear whether the slight
increase in cell invasion after 42 h for the Crk/CrkL double
knockdown cells reﬂects delayed cell invasion or invasion of
newly proliferating cells. These results demonstrate both a
prominent role for CrkL and an essential, overlapping role for
Crk and CrkL in GBM cell invasion. The results of these cell

migration and invasion experiments are consistent with those
in our previous report (53).
Effects of overexpression following knockdown
We investigated whether the effects of gene knockdown
were reversible and rescuable by re-expression of individual
proteins. To accomplish this task, we induced Crk/CrkL
double knockdown ﬁrst and then harvested cells at 3 DPT to
transfect them with synRNA for Flag-tagged CrkII, CrkI, or
CrkL. Examination of the protein levels at 4 DPT after the two
transfections showed expression of both the endogenous, residual CrkII, CrkI, and CrkL and the overexpressed Flagtagged counterparts, although Flag-tagged CrkII and CrkI
were detected only with anti-Crk and anti-CrkL antibodies
(Fig. 7, A and B). Detection of overexpressed Flag-tagged
proteins using an anti-Flag antibody suggested that the level
of Flag-tagged CrkL was much higher than Flag-tagged CrkII
or CrkI (Fig. 7B, inset). Analyses of cell proliferation indicate
that overexpression of CrkII moderately increased cell proliferation (Fig. 7, C and D). On the other hand, cell adhesion to
ﬁbronectin was not restored by overexpression of any of these
proteins (Fig. 7E). The morphological alterations caused by the
Crk/CrkL double knockdown were modestly rescued by CrkL
overexpression (Fig. S7). Examination of cell migration suggests that only CrkL overexpression restored the migration of
cells with Crk/CrkL double knockdown (1.02 ± 0.07 at 14 h,
compared with 0.18 ± 0.02 at 14 h for double knockdown only)
(Fig. 7F). We also examined cell invasion to test whether
overexpression of CrkII, CrkI, and CrkL could rescue defects
caused by Crk/CrkL double knockdown. Defective cell invasion resulting from Crk/CrkL double knockdown was restored
by CrkL overexpression (0.76 ± 0.13 at 30 h, compared with
0.20 ± 0.05 at 30 h for double knockdown only) (Fig. 7G). A
modest rescue of cell migration and invasion by CrkL overexpression in an independent experiment (data not shown)
together with the failure of rescue by CrkII or CrkI overexpression suggests that the defects induced by Crk/CrkL
knockdown may be partially irreversible. Nevertheless, the
rescue by CrkL overexpression, together with the prominent
defects caused by CrkL knockdown, implies that CrkL plays
predominant roles in cell migration and invasion in the GBM
cell line U-118MG.
Quantiﬁcation of Crk and CrkL proteins
Because two different antibodies have been used to detect
CrkII and CrkL, the relative abundance of the two proteins in
the cells was not determined. To quantify expression levels of
Crk and CrkL proteins in mammalian cells, we constructed
prokaryotic expression plasmids for CrkII, CrkI, and CrkL with
epitope tags, glutathione-S-transferase (GST) and Flag, at N
termini and C termini. Then, we puriﬁed proteins without the
GST tag that still harbor the Flag tag. SDS-PAGE and Coomassie Blue staining of puriﬁed proteins exhibited a single
band with the expected size and clean background (Fig. S9A),
suggesting that proteins were pure. Then, we calculated the
purity of the proteins by measuring densities of the major
J. Biol. Chem. (2021) 296 100390
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Figure 7. Effects of overexpression following Crk and CrkL knockdown. U-118MG cells were ﬁrst electroporated with Crk siRNA 10 (40 pmol) and CrkL
siRNAs 22 (20 pmol) plus 24 (20 pmol) together. At 3 DPT, the cells were harvested, electroporated again with synRNA of Flag-tagged CrkII (6 μg), CrkI (6 μg),
or CrkL (2 μg), and re-plated for the various assays. The amount of synRNA corresponds to approximately 4.4 pmol for CrkL, which produced an effective
transfection with synGFP (Fig. S1) and in our previous study (52). A, at 4 DPT, total cell lysates were obtained for Western blot analyses. Protein levels upon
siRNA transfection were compared with those upon electroporation without synRNA. Vinculin levels were measured as controls. B, protein bands were
quantiﬁed using the Odyssey system, calculated as percentages of the control (none) signal, and their mean ± SD values are shown. Inset, protein bands
detected with anti-Flag antibody were quantiﬁed, calculated as percentages of the maximal signal (dKD + CrkL-Flag), and their mean ± SD values are shown.
The signals from the other three samples were negligible. C, proliferation of U-118MG cells electroporated ﬁrst with siRNAs and then again with synRNA was
quantitatively measured using WST-1. The A450–A690 values are presented in the logarithmic scales. D, exponential trendlines for the WST-1 assay graphs were
drawn and their slopes, the coefﬁcients of x, are presented as the rates for exponential cell growth. *p < 0.05, compared with double knockdown only. E–G, U118MG cells electroporated ﬁrst with siRNAs and then again with synRNA were plated onto an E-Plate 16, and two CIM-Plate 16 without and with Matrigel
coating for cell adhesion (E), migration (F), and invasion (G) using the xCELLigence system according to the Experimental procedures. Cell index values were
obtained from four wells for each sample, and their mean ± SD values are shown. Three independent experiments were carried out, and the results were
reproducible. CIM, cell invasion and migration; Crk, CT10 regulator of kinase; CrkL, Crk-like; DPT, days posttransfection; NT1, nontargeting siRNA 1.

bands in comparison with the entire gel lane. The ratios of the
major bands to the whole lanes were 98 ± 9% for CrkII, 91 ±
7% for CrkI, and 91 ± 13% for CrkL (Fig. S9B), suggesting
preparation of highly puriﬁed proteins. As shown in Figure 8,
A–C, U-118MG cell lysates were compared with known
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concentrations of puriﬁed proteins, and the protein concentrations in the cell lysates were determined. Figure 8F indicates
that 1.67 ± 0.25 ng of CrkII and 3.24 ± 1.30 ng of CrkL were
present in the 5 μg cell lysate. As CrkI bands were much
weaker than CrkII bands in our Western blot experiments,

Cell migration is the outcome of Crk and CrkL

A

B

C

Anti-Crk

50
38

II

30
25

I

Anti-CrkL
II

Anti-Crk
L

L

II

II

I

I

CrkII-Flag

D

Lys 4
Lys 5
Lys 6
0
0.03
0.1
0.3
1
3
0
10
30
100

Lys 1
Lys 2
Lys 3
0
0.03
0.1
0.3
1
3
10
30
100

Lys 1
Lys 2
Lys 3
0
0.03
0.1
0.3
1
3
10
30
100

15

CrkL-Flag

E

Anti-Flag

CrkI-Flag

CrkII-Flag

Anti-Flag

50

II/L

38
30
25

II

0.03
0.1
0.3
1
3
10
30
0.03
0.1
0.3
1
3
10
30

15

CrkII-Flag

CrkL-Flag

4
3
2
1
0

CrkII CrkI CrkL

CrkII-Flag

H

I

100000
8

1000

1000

6
4
2
0

10000

10000
Anti-Flag signal

5

Protein (ng)

CrkI-Flag

G
…
Protein number/cell (million)

F

0
0.03
0.1
0.3
1
3
10
0
0.03
0.1
0.3
1
3
10

I

CrkII CrkI CrkL

100

100

10
1
0

CrkII-Flag
CrkL-Flag

10

CrkII-Flag
CrkI-Flag

1
1
10
1
10
100
[Purified protein], ng [Purified protein], ng

Figure 8. Quantiﬁcation of Crk and CrkL proteins using puriﬁed proteins. A–C, Crk and CrkL proteins were detected using anti-Crk (A and C) or anti-CrkL
(B) antibodies from three different lysates prepared from U-118MG cells without any transfection (5 μg per lane). The indicated concentrations (ng) of
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drawn for the puriﬁed protein, and a fourth-order polynomial trendline was obtained using the Microsoft Excel program. The trendline was used to
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only 0.09 ± 0.01 ng of CrkI was present. Calculation of the
protein molecule numbers indicated 3.2 million of CrkII and
6.2 million of CrkL proteins in one U-118MG cell (Fig. 8G).
On the other hand, the number of CrkI proteins was much
lower, with 0.25 million. Comparing the reactivities of the antiFlag antibody among the puriﬁed proteins suggests that the
antibody reactivities are comparable among CrkII, CrkI, and
CrkL (Fig. 8, D, E, H, and I). Together, these results suggest
that CrkL is expressed more abundantly than CrkII and CrkI,
with CrkI the least abundant protein among the three proteins.

Discussion
Crk and CrkL are overexpressed in human GBM tissues, and
the overexpression contributes to poor prognosis (8–10, 31).
Overexpression of CrkI was reported to increase cell motility

and invasion in U87MG cells in a study in which the roles of
CrkII and CrkL were not examined (8). On the other hand, two
research groups studied the effects of Crk or CrkL knockdown
in GBM cell lines. Wang et al. (31) established three KMG4 cell
lines with stable Crk knockdown. All three Crk knockdown cell
lines showed reduced protein levels for CrkII and CrkI. The
speciﬁcity of the stable knockdown is less clear because the
researchers did not examine the effects of shRNAs on CrkL
expression. The Crk knockdown partially inhibited the cell
adhesion to laminin but not to ﬁbronectin, cell motility assessed
by the wound-healing assay, anchorage-dependent cell proliferation, soft agar colony formation, and in vivo tumor growth.
Lv et al. (32) induced CrkL knockdown using CrkL siRNAs in
U87 and U251 GBM cell lines. They did not examine the potential effects of the CrkL siRNA on the expression of CrkII and
CrkI. CrkL knockdown partially inhibited TGFβ-induced
J. Biol. Chem. (2021) 296 100390
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migration and soft agar colony formation of the two GBM cell
lines. Although the two knockdown studies demonstrated the
important roles of Crk and CrkL in GBM cells, the respective
contributions remained unclear.
Crk and CrkL are also elevated in other types of cancer and
suggested as therapeutic targets. Despite their crucial overlapping functions in several biological processes, their potential overlapping roles in tumorigenesis have not received much
attention. Previously, we used the Cre-loxP recombination to
induce single and double knockouts of Crk and CrkL in
knockout mouse models and at the cellular level and studied
distinct and overlapping functions of Crk and CrkL in tissue
development and cellular processes. In this study, we took a
gene knockdown approach to induce individual and combined
knockdown of Crk and CrkL in human GBM cell lines.
Establishing stable cell lines requires a long-term selection
in vitro, which is susceptible to unrecognized changes in
cellular properties with potential changes in the outcome of
the study. Short-term induction of gene knockdown using
siRNAs is an alternative approach to avoid this problem if the
efﬁciency of knockdown is high. Previously, we achieved a
rapid and efﬁcient transfection of ﬁbroblasts with synRNA
using the Neon electroporation system (52). Here, we used the
same system and achieved an efﬁcient transfection of a GBM
cell line with siRNAs. Because Crk and CrkL are structurally
similar to each other, we carefully examined the crossactivities of siRNAs. In addition to examining the protein
levels of CrkII, CrkI, and CrkL as well as control proteins, we
compared cellular phenotypes induced by multiple siRNAs.
Testing multiple siRNAs together with a close examination
and conservative interpretation of the correlation between the
knockdown effects and other phenotypes allowed us to tease
out nonspeciﬁc effects from speciﬁc knockdown effects. For
example, if two siRNAs exhibited similar knockdown effects in
Western blot experiments, but only one siRNA showed additional cellular phenotypes, we interpreted the additional phenotypes as nonspeciﬁc effects. By taking this approach, we
were able to select more speciﬁc and potent siRNAs.
Selected siRNAs for Crk and CrkL were used to induce
individual and combined knockdown in U-118MG cells, and a
range of cellular phenotypes were examined. Crk knockdown
did not affect cell morphology, proliferation, adhesion, and
invasion. In contrast, CrkL knockdown caused modest changes
in cell morphology, proliferation, adhesion, and invasion.
These phenotypic changes were augmented by Crk/CrkL
double knockdown, compared with CrkL knockdown. On the
other hand, cell migration was delayed by Crk knockdown with
slower rates of migration, but the maximal cell migration was
comparable to controls. In contrast, CrkL knockdown substantially inhibited cell migration with slower rates of cell
migration and reduced the maximal migration. It is unclear
why Crk and CrkL affected GBM cell migration differently.
One clue is that Crk knockdown did not affect cell morphology
or proliferation. Thus, it may take more time, in the absence of
Crk, for cells to reorganize cytoskeletal structures in response
to changes in the extracellular environment. Cells may eventually catch up and complete cytoskeletal reorganization
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involved in cell spreading and proliferation. It should be noted
that cell morphology and proliferation were analyzed at a
single time point each day, whereas real-time measurement of
cell migration occurred over a prolonged period. If we had
measured only the maximum level of migration, we might have
missed delayed cell migration induced by Crk knockdown.
This postulation reafﬁrms the advantage of impedance-based
real-time measurement of cell migration, as reported
recently (53). However, this interpretation seems to conﬂict
with a lack of inhibitory effects on cell adhesion and invasion
by Crk knockdown, both of which were also measured in real
time. These results indicate that there may be other mechanisms of Crk function. CrkL appears to be an indispensable
component of the cytoskeletal machinery in U-118MG cells.
Cells lacking CrkL failed to complete cytoskeletal reorganization upon changes in extracellular environments, leading to
partially defective cell spreading, proliferation, and migration.
Our determination of the protein molecule number for
CrkII, CrkI, and CrkL provides quantitative insights into the
actions of Crk and CrkL. Using puriﬁed proteins as the standards, we quantiﬁed Crk and CrkL proteins in the cell lysate
and protein molecule numbers in a single GBM cell. CrkL is
expressed more abundantly than CrkII and CrkI, suggesting
that the more abundant expression of CrkL may attribute to
the predominant role of CrkL. U-118MG cells may have an
intracellular environment that favors CrkL over CrkII and
CrkI, leading to a higher overexpression of synthetic CrkL
mRNA and a subsequent rescue of the phenotypes.
Although Crk and CrkL appear to act differently during cell
migration, Crk/CrkL double knockdown completely blocked
migration, suggesting that Crk and CrkL cooperate to play
essential overlapping roles in migration of the GBM cell model
we tested. More prominent inhibition of cell proliferation,
adhesion, and invasion by Crk/CrkL double knockdown than
that caused by CrkL knockdown indicates that some of the Crk
functions can be revealed only in the absence of CrkL. Because
Crk knockdown alone did not reveal contributions of Crk to
these cellular functions, our study demonstrates the importance of combining single and double knockdown strategies to
fully understand the functions of Crk and CrkL in cancer.
The phosphorylation level of p130Cas correlated well with
the protein levels of Crk and CrkL. The substantial decrease in
the phospho-p130Cas level with Crk/CrkL double knockdown
in GBM cells is consistent with our previous studies with ﬁbroblasts (51, 52) and colorectal and pancreatic cancer cell
lines (42). p130Cas is a key binding partner of Crk and CrkL
and plays important roles in actin cytoskeleton remodeling,
contributing to cell adhesion, spreading, and motility (56).
Thus, it will be interesting to investigate whether the Crk/
CrkL-p130Cas interaction is critical in the cellular functions
mediated by Crk/CrkL and p130Cas.
Because GBM is divided into several subtypes and is highly
heterogeneous (3, 57–59), further in vitro and in vivo studies
using additional GBM cell lines and patient tumor tissues are
needed to validate the overlapping functions of Crk and CrkL
in GBM. Nevertheless, our study suggests that targeting both
Crk and CrkL at the same time may need to be considered to
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achieve effective therapy. Our study demonstrates that
migration of U-118MG cells depends entirely on Crk and
CrkL, and that real-time measurement of U-118MG cell
migration is a reliable assay to investigate Crk and CrkL activity during development of inhibitors of these proteins. By
comparing the migration rates and the maximum levels of
migration between control and test groups, we hope to identify
drug candidates that inhibit Crk, CrkL, or both.

Experimental procedures
Cell culture and transfection
Human GBM cell lines, including U-118MG, were purchased from American Type Culture Collection (ATCC),
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(ATCC) supplemented with 5% fetal bovine serum (FBS)
(HyClone) and 1% penicillin/streptomycin (Gibco) at 37  C
under 5% CO2 and cryopreserved for future experiments according to the ATCC’s instructions. Before we started our
planned experiments, the cell lines were authenticated using
short tandem repeat proﬁling through the ATCC. For the gene
knockdown study, human CRK siRNAs 7 (J-010503-07), 8 (J010503-08), 9 (J-010503-09), and 10 (J-010503-10) and human
CRKL siRNAs 6 (J-012023-06), 7 (J-012023-07), 8 (J-01202308), and 9 (J-012023-09), as well as nontargeting siRNA 1
(NT1, D-001818-01), were purchased from GE Dharmacon.
Human CRKL siRNAs 22 (s3522), 23 (s3523), and 24 (s3524)
were purchased from Ambion. The synRNAs were synthesized
in vitro using the Megascript T7 reaction (Invitrogen) and the
EPAP poly-A tailing system (Ambion), as described previously
(52). For the transfection of GBM cells with siRNAs or synRNA, cells were harvested and counted, and 1 × 105 cells were
gently mixed with the indicated amounts (μg in 10 μl cell
suspension) of RNAs. Then, the U-118MG cells were placed in
a 10 μl Neon tip and electroporated with three pulses at
1350 V for 10 ms using the Neon transfection system (Life
Technologies). The manufacturer’s instructions for the Neon
system recommend using 0.5 to 3 μg DNA or 10 to 200 nM
siRNA for electroporating cells to plate in a six-well with 2 ml
of culture medium. We achieved efﬁcient transfection of U118MG cells by using 2 μg synGFP, as shown in Figure S1.
Because the volume for electroporation is limited, we ﬁrst used
20 nM to test siRNAs, which corresponds to 40 pmol. However, because the seeding density of cells and the amount of
culture medium changed depending on the type of analysis, we
used moles rather than molar concentrations to indicate more
accurately how much siRNA was used for each 10 μl electroporation. Where indicated, cells were electroporated with 2 to
6 μg synRNA of Flag-tagged CrkII, CrkI, or CrkL. The 2 μg
synRNA corresponds to approximately 4.4 pmol for CrkII and
CrkL and 5.7 pmol for CrkI, which produced effective transfection of ﬁbroblasts in our previous study (52). Transfected
cells for each sample were pooled in the culture medium
without antibiotics and seeded onto 48-well plates for cell
proliferation analysis using WST-1 (Roche) (9000 cells/well),
8-well culture slides (BD) for immunocytochemistry
(9000 cells/well), and 35 mm dishes for protein expression

analysis using Western blot analysis (100,000 cells/dish).
Where indicated, transfected cells were plated onto 100 mm
dishes and cultured for 3 days before they were harvested for
the second transfection and subsequent analyses, including
real-time measurement of cell adhesion (10,000 cells/well),
migration (100,000 cells/well), and invasion (100,000 cells/
well). Images of live cells were taken using the EVOS system
with PL FL 10x LWD PH (ThermoFisher Scientiﬁc) before cell
lysates were prepared from 35 mm dishes.
Western blot analysis
Both preparations of GBM cell lysates and Western blot
analyses using the Odyssey infrared imaging system (Li-Cor
Biosciences) were described previously (60). Protein bands
from at least three Western experiments were quantiﬁed using
the Odyssey system, and their mean ± SD values are shown in
the graph. The following antibodies were used: anti-Crk
(610035) and anti-p130Cas (610272) antibodies are from BD
Biosciences; anti-CrkL (sc-319) antibody is from Santa Cruz
Biotechnology Inc; anti-alpha-tubulin (T9026) antibody is
from Sigma; antibodies against phospho-p130Cas (Tyr410;
4011) and vinculin (4970) are from Cell Signaling Technology.
Two prestained protein ladders, Chameleon Duo (Li-Cor
Biosciences) and SeeBlue Plus2 (ThermoFisher Scientiﬁc) were
used to determine the size of proteins.
Cell proliferation assay using WST-1
Cell proliferation was measured using cleavage of the
tetrazolium salt WST-1 (Roche Applied Science) into a watersoluble formazan by cellular enzymes, as described previously
(52). Cells were seeded in quadruplicate at 9 × 103 cells/well
onto 48-well plates after transfection. For the cell proliferation
measurement, cells were incubated with 200 μl/well of fresh
culture medium plus 20 μl/well of WST-1 stock solution
provided by the manufacturer for 2 h in a CO2 incubator. As a
background control, WST-1 was added to the medium without
cells. At the end of the incubation, the conditioned medium
was mixed for 1 min on a shaker to make the medium homogenous, and absorbances at both 450 and 690 nm were read
using the Inﬁnite M200 PRO NanoQuant microplate reader
(Tecan) for measurement and reference wavelengths, respectively. The reference value was subtracted from the measurement value, and the A450–690 value was multiplied by 1000 for
easy calculation and presentation purposes. Where indicated,
results were normalized to the percentages of the value obtained at the ﬁrst measurement for the sample (1 DPT, or 4
DPT if cells were harvested at 3 DPT). Results were plotted on
a graph using Microsoft Excel with the x-axis for DPT and the
y-axis for A450–690 in the logarithmic scale. An exponential
trendline was obtained by using the Microsoft Excel program,
and the slope of the trendline, which is the coefﬁcient of x, is
presented as the rate for exponential cell growth.
Impedance-based real-time cell assays
Cell adhesion to ﬁbronectin-coated dishes was measured in
real-time using the xCELLigence Real-Time Cell Analyzer
J. Biol. Chem. (2021) 296 100390

13

Cell migration is the outcome of Crk and CrkL
Biotechnology, sc-319) antibodies, followed by APCconjugated anti-mouse IgG (BD Biosciences, 550826) and
BV421-conjugated anti-rabbit IgG (BD Biosciences, 565014).
Cells were analyzed by ﬂow cytometry using the On-chip Sort
(On-chip Biotechnologies).

(Agilent) according to the manufacturer’s instructions. Brieﬂy,
E-plate 16 was coated with 20 μl/well of 10 μg/ml ﬁbronectin.
Next, 50 μl/well of DMEM containing 0.5% FBS was added to
the E-Plate 16 for the baseline measurement. Then, 1 ×
104 cells in 100 μl of DMEM containing 0.5% FBS were added
to each well of the E-Plate 16, and impedance was measured
every 5 min for the indicated time. Cell migration was also
measured in real time using xCELLigence, as described previously (53). Brieﬂy, the upper and lower chambers of a cell
invasion and migration (CIM) plate with 16 wells (CIM-Plate
16) were ﬁlled with 50 μl of low-serum (0.5% FBS) medium
and 160 μl of high-serum (10% FBS) medium, respectively.
After the upper and lower chambers were assembled as
instructed by the manufacturer, the CIM-Plate was placed in a
CO2 incubator for 30 min to establish the serum gradient.
Then, the baseline was measured using xCELLigence located
inside a CO2 incubator. After 1 × 105 cells in 100 μl of lowserum medium were added to each well of the upper chamber, the CIM-Plate was kept at room temperature for 30 min
to allow the cells to settle down at the bottom. Then, the CIMPlate was transferred to a cradle of xCELLigence, and changes
in the cell impedance were measured every 10 min for 24 h.
Cell index data were exported to Microsoft Excel for processing and graphical presentation in a time-dependent
manner. The time of starting to measure the impedance after the addition of cells to the CIM-Plate, not the time when
the baseline was measured, was set as the start time for plotting graphs. For the cell invasion assay, the upper chamber of
the CIM-Plate was coated with 2 μg/well of Matrigel (Corning), and the rest of the procedures were the same as the cell
migration assay.

Mouse cDNA sequences of CrkII, CrkI, and CrkL with the
Flag tag were subcloned into the pGEX-4T-3 vector (GE
Healthcare). BL21(DE3) competent cells (New England Biolabs) were transformed with the plasmids, and expression of
the GST-fusion proteins was induced by adding isopropyl β-D1-thiogalactopyranoside to the bacterial culture. Bacterial cells
were harvested, resuspended in phosphate buffered saline, and
lysed mechanically with a sonic dismembrator (Fisher Scientiﬁc). GST-fusion proteins were isolated with glutathione
agarose (Pierce) and treated with thrombin (GE Healthcare) or
reduced glutathione (Fisher Scientiﬁc) to collect the whole
protein or the protein without the GST tag. Concentrations of
puriﬁed proteins were determined by using the Bio-Rad protein assay kit. One microgram of each puriﬁed protein was
loaded on an Invitrogen NuPAGE 4 to 12% Bis-Tris gel
(Thermo Fisher) and separated by SDS-PAGE. For Coomassie
Blue staining, the gel was stained with the GelCode Blue stain
reagent (Thermo Scientiﬁc) according to the manufacturer’s
instructions. The gel was scanned, and its image ﬁle was imported to the Odyssey infrared imaging system (Li-Cor Biosciences). Densities of the major bands and the entire gel lanes
(from 160 to 15 kDa) were quantiﬁed, and the ratios of the
major bands to the entire lanes were calculated to determine
the purity of the bands.

Immunocytochemistry and cytometric analyses

Statistical analysis

Immunostaining of GBM cells cultured on 8-well culture
slides was carried out as previously reported (60) with some
modiﬁcations. High magniﬁcation images of immunostained
cells were captured using a Leica DM6B microscope equipped
with Leica HC FL Fluotar 10x/0.32 PH1, Hamamatsu Orca
Flash 4.0 V3 monochrome, and Leica DFC450 color cameras.
Quantitative assessments of transfection efﬁciency and cell
morphology were performed by the ﬂuorescence imagingbased method using the LAS X program. For quantiﬁcation
of the cytoplasmic and nuclear areas, phalloidin-TRITC and
DAPI images of cells were taken throughout the entire area of
the well. Areas and numbers of DAPI-positive objects were
calculated to obtain the average size of the nucleus for each
ﬁeld of view. Then, the total cytoplasmic area with phalloidin
signals was divided by the number of DAPI-positive objects to
obtain the average size of the cytoplasm for each ﬁeld of view.
The values from all the ﬁelds of view were combined to
calculate the overall sizes of the nucleus and cytoplasm.

All quantitative data are presented as mean ± SD. Statistical
analyses of data were carried out using unpaired two-tailed
Student’s t test for comparison between two experimental
groups. Differences were considered to be signiﬁcant when
probability (p) values were <0.05.

Protein puriﬁcation from bacterial cells

Data availability
The data supporting the ﬁndings of this study are contained
in the article and its supporting information. The data that are
described but not shown in the article will be shared upon
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